Document is current
Any future updates will be listed below
-
Authors
Inoue, Daichi
Polaski, Jacob T. http://orcid.org/0000-0001-6570-1789
Taylor, Justin http://orcid.org/0000-0003-4407-6325
Castel, Pau http://orcid.org/0000-0002-4972-4347
Chen, Sisi
Kobayashi, Susumu
Hogg, Simon J.
Hayashi, Yasutaka
Pineda, Jose Mario Bello
El Marabti, Ettaib
Erickson, Caroline
Knorr, Katherine
Fukumoto, Miki
Yamazaki, Hiromi
Tanaka, Atsushi
Fukui, Chie
Lu, Sydney X.
Durham, Benjamin H. http://orcid.org/0000-0001-8090-5448
Liu, Bo
Wang, Eric
Mehta, Sanjoy
Zakheim, Daniel
Garippa, Ralph
Penson, Alex
Chew, Guo-Liang http://orcid.org/0000-0003-4357-1404
McCormick, Frank http://orcid.org/0000-0002-6619-7120
Bradley, Robert K. http://orcid.org/0000-0002-8046-1063
Abdel-Wahab, Omar http://orcid.org/0000-0002-3907-6171
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (R01 HL128239, R01 HL151651, R01 HL128239, R01 HL151651, R01 HL128239)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01 CA251138, 1K08CA230319-01, R01 CA251138, T32 CA009657)
U.S. Department of Defense (W81XWH-12-1-0041, W81XWH-12-1-0041)
Japan Agency for Medical Research and Development (JP19cm0106165, JP20cm0106165)
MEXT | Japan Society for the Promotion of Science (JP20H00537, JP 20H03717)
U.S. Department of Health & Human Services | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (R01 DK103854, R01 DK103854)
Leukemia and Lymphoma Society (8023-20)
- License Information
-
More Information
Article History
Received: 28 May 2020
Accepted: 24 February 2021
First Online: 12 April 2021
Competing interests
: O.A.-W. has served as a consultant for H3B Biomedicine, Foundation Medicine Inc., Merck, Prelude Therapeutics and Janssen and is on the scientific advisory board of Envisagenics Inc., AIChemy and Pfizer Boulder; O.A.-W. received prior research funding from H3B Biomedicine and Loxo Oncology unrelated to the current manuscript. The remaining authors declare no competing interests.
